Important Information
If you are interested in applying for this study, please:
- read the study description.
- review the Visit Planner dates in your location and confirm that you are available for the stated dates.
- If you have not yet registered with us, click on the ‘Register’ button at the top of this page and answer the questions.
- If you have already registered with us, answer the pre-screening questions listed below and submit your interest.
We will then contact you to check your suitability and share the Participant Informed Consent Form for you to read.
Study Description
New Zealand Clinical Research is trialling an investigational medication that is being developed for the treatment of acute (short-term) and chronic (long-term) pain.
Almost 1 in 6 people in New Zealand have reported that they experience chronic pain which affects their quality of life. This medication is being investigated for the first time to evaluate how safe and well tolerated it is, in healthy people.
LTG-305 is designed to work by blocking pathways in the brain that are associated with the sensing of pain.
This is an investigational drug because it has not been approved by MedSafe or other drug regulatory authorities.
This study (2024 FULL 20202) is being funded by Latigo Biotherapeutics, Inc and has been approved by the Health and Disability Ethics Committee.
Requirements
Healthy Males only
- Aged between 18 – 55 years
- BMI (Body Mass Index) between 18 – 32 kg/m2
- Non-smokers/vapers allowed
- Not currently taking any regular prescription medications
- Cold Pressor Test (CPT) – Not have any conditions which affect your skin on your arms and hands, or how you feel pain
What is Involved?
Study visits:
2 x 5-night stays (for a total of 10-nights) + 1 follow-up phone call
Reimbursement:
Up to $6,600 (before tax)